Published Date: 11 Oct 2024
10% of patients in trials leading to eli-cel's approval developed MDS or AML
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer
3.
Do I qualify for a cancer clinical trial?
4.
Healthcare in the Mix in President Biden's Farewell Address
5.
Higher Risk of Kidney Cancer Recurrence After Ablative Therapy
1.
Unlocking the Mysteries of Synovial Sarcoma: A New Hope for Treatment
2.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
3.
Precision Oncology: Tailoring Cancer Treatment for the Individual
4.
The Lung Cancer Shift: From Reactive Treatment to Proactive Precision Medicine
5.
The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
3.
Navigating the Complexities of Ph Negative ALL - Part VII
4.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation